Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial

Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial

Background: An in silico screen was performed to identify FDA approved drugs that inhibit SARS-CoV-2 main protease (Mpro), followed by in vitro viral replication assays, and in vivo pharmacokinetic studies in mice. These studies identified atovaquone as a promising candidate for inhibiting viral rep...

Full description

Bibliographic Details
Main Authors: Mamta K. Jain, James A. De Lemos, Darren K. McGuire, Colby. Ayers, Jennifer L. Eitson, Claudia L. Sanchez, Dena Kamel, Jessica A. Meisner, Emilia V. Thomas, Anita A. Hegde, Satish Mocherla, Joslyn K. Strebe, Xilong Li, Noelle S. Williams, Chao Xing, Mahmoud S. Ahmed, Ping Wang, Hesham A. Sadek, John W. Schoggins
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Pharmacology
Subjects:
COVID-19
clinical trial
atovaquone
placebo controlled
double blind
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.1020123/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.1020123/full

Similar Items